FDA 483 - Lee Pharma Ltd. - November 02, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Lee Pharma Limited, a manufacturer in Hyderabad, India, revealed significant deficiencies in their quality control systems. The firm was cited for failing to validate analytical methods used for process validation and stability samples, and for inadequate storage conditions and packaging simulation for stability samples. Additionally, the inspection found issues with establishing reexamination periods for packaging materials and with written procedures lacking sufficient detail for consistent implementation.
ID · 79200c8f-40d2-4f65-a7b4-7a03f9a69738